Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Cancer
Interventions: DRUG: ridaforolimus|DRUG: MK-0752|DRUG: MK-2206
Sponsor: Merck Sharp & Dohme LLC